First-in-class drug wins TGA tick

Posted 14 November 2022 AM

Last week the TGA waved through two innovative therapies including a dialysis product that CSL just recently added to its pipeline when it completed its mammoth Vifor Pharma acquisition.

The regulator approved the company's Korsuva, a first-in-class kappa opioid receptor agonist, indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here